Apatinib: all 412 studies that test it

Page 2 of 5. Open to participants first (94), then studies with results posted, then the rest; newest registration first within each.

• A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTCCompletedNCT03092895Phase 2Results posted
• A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)CompletedNCT03083041Phase 2Results posted
• A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric CancerCompletedNCT03042611Phase 3Results posted
• Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)CompletedNCT02878057Phase 2Results posted
• Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)CompletedNCT02329860Phase 3Results posted
• Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric CancerCompletedNCT01512745Phase 3Results posted
• Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast CancerActive, not recruitingNCT07371910Phase 3
• Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation PneumonitisActive, not recruitingNCT06700421Phase 2
• Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric CancerActive, not recruitingNCT06693128Phase 2
• Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast CancerActive, not recruitingNCT06447623Phase 3
• A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory NeuroblastomaWithdrawnNCT06308575Phase 2
• Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT06281886Phase 2
• KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 BlockadeActive, not recruitingNCT06099821Phase 2
• Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II TrialStatus unknownNCT05942573Phase 2
• Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast CancerActive, not recruitingNCT05759572Phase 2
• A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract CancerCompletedNCT05742750Phase 1/2
• Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract CancerActive, not recruitingNCT05451290Phase 2
• A Study Comparing Four Different Rivoceranib Tablets in Healthy ParticipantsCompletedNCT05287360Phase 1
• Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma （SPARE-02）CompletedNCT05235100Phase 2
• An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced GastrointestinalStatus unknownNCT05225844Phase 2
• Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric CancerCompletedNCT05223088Phase 2
• Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCCStatus unknownNCT05171309Phase 2
• Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCCCompletedNCT05156970Phase 2
• Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine CarcinomasStatus unknownNCT05142865Phase 2
• Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous CellStatus unknownNCT05049681Phase 3
• Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 TherapyStatus unknownNCT05029453Phase 4
• Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.CompletedNCT05027386Phase 1/2
• Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLCStatus unknownNCT05001412Phase 1
• First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical CancerTerminatedNCT04974944Phase 2
• A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLCStatus unknownNCT04950400Not applicable
• Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric AdenocarcinomaStatus unknownNCT04948125Phase 2
• SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular CarcinomaCompletedNCT04930315Phase 2
• Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung CancerStatus unknownNCT04901754Phase 2
• SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and ChemotherapyStatus unknownNCT04878107Phase 2
• Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the StomachWithdrawnNCT04863430Phase 2
• A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and OxaliplatinStatus unknownNCT04850040Phase 2
• Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver MetastasesStatus unknownNCT04832204Phase 2
• Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory OsteosarcomaSuspendedNCT04824352Phase 2
• Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular CarcinomaStatus unknownNCT04724226Phase 2
• Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.CompletedNCT04720131Phase 2
• PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal CancerStatus unknownNCT04715633Phase 2
• Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory OsteosarcomaCompletedNCT04690231Not applicable
• Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLCStatus unknownNCT04683198Phase 2
• Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICCWithdrawnNCT04682249Phase 2
• Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line ImmunotherapyStatus unknownNCT04670913Phase 2
• A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）Status unknownNCT04659785Phase 1/2
• Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract CancerCompletedNCT04642664Phase 2
• A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationActive, not recruitingNCT04639180Phase 3
• Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid CancerStatus unknownNCT04612894Phase 2
• Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction AdenocarcinomaStatus unknownNCT04609176Phase 2
• Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian CancerStatus unknownNCT04590625Phase 2
• Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment FailureActive, not recruitingNCT04586088Phase 2
• Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric CancerStatus unknownNCT04572542Phase 1/2
• Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid TumorsStatus unknownNCT04569916Phase 2
• TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar CarcinomaActive, not recruitingNCT04559607Not applicable
• Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04548271Phase 2
• Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04547088Phase 2
• Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular CarcinomaActive, not recruitingNCT04521153Phase 2/3
• A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer PatientsCompletedNCT04517357Phase 2
• Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCLStatus unknownNCT04476459Phase 1/2
• Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung AdenocarcinomaStatus unknownNCT04459078Phase 2
• A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor SubjectsCompletedNCT04457180Phase 1
• A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）Status unknownNCT04453930Phase 2
• A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPSStatus unknownNCT04447274Phase 2
• Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell CarcinomaStatus unknownNCT04440917Phase 2
• Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLCStatus unknownNCT04425135Phase 2
• The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic CarcinomaStatus unknownNCT04415385Phase 2
• A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal FunctionStatus unknownNCT04414852Phase 1
• Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral MelanomaStatus unknownNCT04397770Phase 2
• Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell CarcinomaCompletedNCT04393506Phase 1
• Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC PatientsStatus unknownNCT04390984Phase 1
• Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian CancerStatus unknownNCT04383977Phase 2
• Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade OsteosarcomaStatus unknownNCT04351308Phase 2
• Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaCompletedNCT04350190Phase 2
• A Food Effect Study of Apatinib Mesylate in Healthy SubjectsCompletedNCT04341090Phase 1
• A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.TerminatedNCT04335006Phase 3
• A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor SubjectsCompletedNCT04322552Phase 1
• A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBCStatus unknownNCT04303741Phase 2
• Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid TumorStatus unknownNCT04282278Phase 2
• Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric CancerActive, not recruitingNCT04267549Phase 2
• Apatinib for Inoperable Advanced ChondrosarcomaCompletedNCT04260113Not applicable
• Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric CancerStatus unknownNCT04258644Phase 2
• Clinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade GliomasStatus unknownNCT04253873Phase 2
• Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine CancerStatus unknownNCT04239443Phase 2
• A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based ChemotherapyStatus unknownNCT04229615Phase 3
• Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Phase 2/3
• The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver CancerStatus unknownNCT04204577Phase 2
• Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)Status unknownNCT04203485Phase 3
• Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal CancerStatus unknownNCT04202978Phase 1/2
• Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung CancerStatus unknownNCT04201990Phase 1/2
• Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric CancerCompletedNCT04195828Phase 2
• Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical StudyStatus unknownNCT04190745Phase 2
• First-line Chemotherapy for Recurrent Cervical CancerCompletedNCT04188847Phase 2
• Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04182724Phase 1/2
• Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid CancersStatus unknownNCT04180007Phase 2
• PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric CancerStatus unknownNCT04174339Not applicable
• Effect and Safety of Apatinib on Radiation-Induced Brain InjuryStatus unknownNCT04152681Phase 2
• Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLCStatus unknownNCT04133337Phase 1/2
• Appatinib Combined With S-1 in the Treatment of Small Cell Lung CancerStatus unknownNCT04128800Phase 2
• Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue SarcomaStatus unknownNCT04126811Phase 2

← Apatinib overview